{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:37:32Z","timestamp":1786711052521,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00836-z","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:00:56Z","timestamp":1786708856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences for Relapsed\/Refractory Mantle Cell Lymphoma Among Patients and Physicians in China: A Discrete Choice Experiment"],"prefix":"10.1007","author":[{"given":"Jiachen","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-6220","authenticated-orcid":false,"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102318","author":"H Wan","year":"2025","unstructured":"Wan H, Ren W, Yang M, Nie M, Wasik AM, Du L, et al. Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102318.","journal-title":"Cell Rep Med"},{"key":"836_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/aol.2019.03.01","author":"L Veloza","year":"2016","unstructured":"Veloza L, Ribera-Cortada I, Campo E. Mantle cell lymphoma pathology update in the 2016 WHO classification. Ann Lymphoma. 2016. https:\/\/doi.org\/10.21037\/aol.2019.03.01.","journal-title":"Ann Lymphoma"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","volume":"36","author":"N Monga","year":"2020","unstructured":"Monga N, Garside J, Quigley J, Hudson M, O\u2019Donovan P, O\u2019Rourke J, et al. Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020;36:843\u201352. https:\/\/doi.org\/10.1080\/03007995.2020.1742101.","journal-title":"Curr Med Res Opin"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"IJH45","DOI":"10.2217\/ijh-2023-0002","volume":"12","author":"SJ Keating","year":"2023","unstructured":"Keating SJ, Inguva S, Qian J, Shah R, Chirikov V. Real-world treatment patterns, healthcare resource utilization and total cost of care in mantle cell lymphoma from US commercial claims. Int J Hematol Oncol. 2023;12:IJH45. https:\/\/doi.org\/10.2217\/ijh-2023-0002.","journal-title":"Int J Hematol Oncol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai Q, Zhang W, Liu S, Liu H, Sun X, et al. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis. Cancer Med. 2023;12:13204\u201316. https:\/\/doi.org\/10.1002\/cam4.6009.","journal-title":"Cancer Med"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2461","volume":"36","author":"Y Miao","year":"2018","unstructured":"Miao Y, Cao L, Sun Q, Li XT, Wang Y, Qiao C, et al. Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: a single-centre analysis. Hematol Oncol. 2018;36:121\u20137. https:\/\/doi.org\/10.1002\/hon.2461.","journal-title":"Hematol Oncol"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood.2023022352","volume":"145","author":"CE Ryan","year":"2024","unstructured":"Ryan CE, Armand P, LaCasce AS. Frontline treatment of mantle cell lymphoma. Blood. 2024;145:663\u201372. https:\/\/doi.org\/10.1182\/blood.2023022352.","journal-title":"Blood"},{"key":"836_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, R\u00e4ty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410\u20138. https:\/\/doi.org\/10.1111\/bjh.14241.","journal-title":"Br J Haematol"},{"key":"836_CR9","volume-title":"Guidelines of Chinese Society of Clinical Oncology (CSCO) lymphoid malignancies","author":"Chinese Society of Clinical Oncology Guideline Working Group","year":"2024","unstructured":"Chinese Society of Clinical Oncology Guideline Working Group. Guidelines of Chinese Society of Clinical Oncology (CSCO) lymphoid malignancies. Beijing: People\u2019s Medical Publishing House; 2024."},{"key":"836_CR10","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (version 4.2026). National Comprehensive Cancer Network. [cited 2024 July 12]. https:\/\/www.nccn.org\/guidelines\/nccn-guidelines. Accessed 12 Jul 2024."},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/bloodadvances.2025017160","volume":"10","author":"T Phillips","year":"2026","unstructured":"Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, et al. Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma. Blood Adv. 2026;10:1457\u201368. https:\/\/doi.org\/10.1182\/bloodadvances.2025017160.","journal-title":"Blood Adv"},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183:578\u201387. https:\/\/doi.org\/10.1111\/bjh.15567.","journal-title":"Br J Haematol"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3324\/haematol.2024.286205","volume":"110","author":"BT Grainger","year":"2024","unstructured":"Grainger BT, Cheah CY. \u201cThe end of the golden weather\u201d: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors. Haematologica. 2024;110:576\u201387. https:\/\/doi.org\/10.3324\/haematol.2024.286205.","journal-title":"Haematologica"},{"key":"836_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70233","volume":"9","author":"M Jerkeman","year":"2025","unstructured":"Jerkeman M, Aurer I, Campo E, Cheah CY, Clark J, Doorduijn J, et al. EHA\u2013EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. HemaSphere. 2025;9:e70233. https:\/\/doi.org\/10.1002\/hem3.70233.","journal-title":"HemaSphere"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3760\/cma.j.cn112152-20250605-00260","volume":"48","author":"Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, China Anti-Cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists","year":"2026","unstructured":"Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, China Anti-Cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists. China lymphoma diagnosis and treatment guideline (2026 edition). Zhonghua Zhong Liu Za Zhi. 2026;48:263\u2013309. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20250605-00260.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"43","key":"836_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3760\/cma.j.issn.0253-2727.2022.07.001","volume":"2022","author":"Hematology Oncology Committee of China Anti-Cancer Association L& LGS of H at CMA","year":"2022","unstructured":"Hematology Oncology Committee of China Anti-Cancer Association L& LGS of H at CMA. The consensus of the diagnosis and treatment of mantle cell lymphoma in China (2022 version). Chin J Hematol. 2022;2022(43):529. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.07.001.","journal-title":"Chin J Hematol."},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1182\/blood-2023-185803","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen Y, Huang R, Xiao Y, Jiang F, Yi S, et al. Real-world patient characteristics, treatment patterns, and outcomes in patients with mantle cell lymphoma in China: a retrospective analysis using a real-world database. Blood. 2023;142:7361. https:\/\/doi.org\/10.1182\/blood-2023-185803.","journal-title":"Blood"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1080\/10428194.2024.2338851","volume":"65","author":"M Alzahrani","year":"2024","unstructured":"Alzahrani M, Villa D. Management of relapsed\/refractory mantle cell lymphoma. Leukemia Lymphoma. 2024;65:1044\u201354. https:\/\/doi.org\/10.1080\/10428194.2024.2338851.","journal-title":"Leukemia Lymphoma"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW de Bekker-Grob","year":"2012","unstructured":"de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145\u201372. https:\/\/doi.org\/10.1002\/hec.1697.","journal-title":"Health Econ"},{"key":"836_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-025-01495-y","author":"S Nouwens","year":"2025","unstructured":"Nouwens S, Marceta S, Bui M, van Dijk D, Groothuis-Oudshoorn C, Veldwijk J, et al. The evolving landscape of discrete choice experiments in health economics: a systematic review. Pharmacoeconomics. 2025. https:\/\/doi.org\/10.1007\/s40273-025-01495-y.","journal-title":"Pharmacoeconomics"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a users\u2019 guide. Pharmacoeconomics. 2008;26:661\u201377. https:\/\/doi.org\/10.2165\/00019053-200826080-00004.","journal-title":"Pharmacoeconomics"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. Pharmacoeconomics. 2023;41:43\u201357. https:\/\/doi.org\/10.1007\/s40273-022-01198-8.","journal-title":"Pharmacoeconomics"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/fon-2020-0018","volume":"16","author":"J Eriksson","year":"2020","unstructured":"Eriksson J, Landfeldt E, Ireland S, Jackson C, Wyatt E, Gaudig M. Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany. Future Oncol England. 2020;16:859\u201368. https:\/\/doi.org\/10.2217\/fon-2020-0018.","journal-title":"Future Oncol. England"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","volume":"42","author":"J Ride","year":"2024","unstructured":"Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A reporting checklist for discrete choice experiments in health: the DIRECT checklist. Pharmacoeconomics. 2024;42:1161\u201375. https:\/\/doi.org\/10.1007\/s40273-024-01431-6.","journal-title":"Pharmacoeconomics"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37:201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang J-C, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22:157\u201360. https:\/\/doi.org\/10.1016\/j.jval.2018.07.876.","journal-title":"Value Health"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40271-018-0324-6","volume":"12","author":"D Campbell","year":"2019","unstructured":"Campbell D, Erdem S. Including opt-out options in discrete choice experiments: issues to consider. Patient. 2019;12:1\u201314. https:\/\/doi.org\/10.1007\/s40271-018-0324-6.","journal-title":"Patient"},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/sifp.12280","volume":"56","author":"EK Harrington","year":"2025","unstructured":"Harrington EK, Ouma DC, Pike M, Awuor M, Kimanthi S, Onono M, et al. Exploring adolescents\u2019 contraceptive preferences and trade-offs: findings from a discrete choice experiment in Kenya. Stud Fam Plann. 2025;56:41\u201364. https:\/\/doi.org\/10.1111\/sifp.12280.","journal-title":"Stud Fam Plann"},{"key":"836_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8:373\u201384. https:\/\/doi.org\/10.1007\/s40271-015-0118-z.","journal-title":"Patient"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","volume":"17","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Marshall DA, Hauber AB, Bridges JFP. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert Rev Pharmacoecon Outcomes Res. 2017;17:531\u201342. https:\/\/doi.org\/10.1080\/14737167.2017.1389648.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"e2318320","DOI":"10.1001\/jamanetworkopen.2023.18320","volume":"6","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhai P, Jiang S, Li C, Li S. Blood donors\u2019 preferences toward incentives for donation in China. JAMA Netw Open. 2023;6:e2318320. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.18320.","journal-title":"JAMA Netw Open"},{"key":"836_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chieco.2020.101538","author":"S Jiang","year":"2020","unstructured":"Jiang S, Gu YY, Yang F, Wu T, Wang H, Cutler H, et al. Tertiary hospitals or community clinics? An enquiry into the factors affecting patients\u2019 choice for healthcare facilities in urban China. China Econ Rev. 2020. https:\/\/doi.org\/10.1016\/j.chieco.2020.101538.","journal-title":"China Econ Rev"},{"key":"836_CR34","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1080\/10428194.2020.1783443","volume":"61","author":"N Khan","year":"2020","unstructured":"Khan N, Feliciano J, Mueller K, He M, Tao R, Korol E, et al. Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma. 2020;61:2630\u20137. https:\/\/doi.org\/10.1080\/10428194.2020.1783443.","journal-title":"Leuk Lymphoma"},{"key":"836_CR35","volume-title":"Stata statistical software: release 19","author":"StataCorp","year":"2025","unstructured":"StataCorp. Stata statistical software: release 19. College Station: StataCorp LLC; 2025."},{"key":"836_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2022.102716","volume":"87","author":"AE Attema","year":"2023","unstructured":"Attema AE, Galizzi MM, Gro\u00df M, Hennig-Schmidt H, Karay Y, L\u2019Haridon O, et al. The formation of physician altruism. J Health Econ. 2023;87:102716. https:\/\/doi.org\/10.1016\/j.jhealeco.2022.102716.","journal-title":"J Health Econ"},{"key":"836_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14:775\u201390. https:\/\/doi.org\/10.1007\/s40271-021-00520-4.","journal-title":"Patient"},{"key":"836_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jviscsurg.2013.10.001","volume":"151","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F. Endpoints in cancer clinical trials. J Visc Surg. 2014;151:17\u201322. https:\/\/doi.org\/10.1016\/j.jviscsurg.2013.10.001.","journal-title":"J Visc Surg"},{"key":"836_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1287\/mnsc.39.8.937","volume":"39","author":"R von Nitzsch","year":"1993","unstructured":"von Nitzsch R, Weber M. The effect of attribute ranges on weights in multiattribute utility measurements. Manag Sci. 1993;39:937\u201343. https:\/\/doi.org\/10.1287\/mnsc.39.8.937.","journal-title":"Manag Sci"},{"key":"836_CR40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175:1389\u201398. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829.","journal-title":"JAMA Intern Med"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood. 2022;139:666\u201377. https:\/\/doi.org\/10.1182\/blood.2021013326.","journal-title":"Blood"},{"key":"836_CR42","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139:3148\u201358. https:\/\/doi.org\/10.1182\/blood.2021014162.","journal-title":"Blood"},{"key":"836_CR43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022353","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023022353.","journal-title":"Blood"},{"key":"836_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(17)33108-2.","journal-title":"Lancet"},{"key":"836_CR45","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104:e211\u20134. https:\/\/doi.org\/10.3324\/haematol.2018.205229.","journal-title":"Haematologica"},{"key":"836_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000362816","volume":"87","author":"D Cella","year":"2014","unstructured":"Cella D, Nowinski CJ, Frankfurt O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology. 2014;87:133\u201347. https:\/\/doi.org\/10.1159\/000362816.","journal-title":"Oncology"},{"key":"836_CR47","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/ppa.S460994","volume":"18","author":"MC Ornstein","year":"2024","unstructured":"Ornstein MC, Rosenblatt LC, Yin X, Del Tejo V, Guttenplan SB, Ejzykowicz F, et al. Treatment preferences among patients with renal cell carcinoma: results from a discrete choice experiment. Patient Prefer Adherence. 2024;18:1729\u201339. https:\/\/doi.org\/10.2147\/ppa.S460994.","journal-title":"Patient Prefer Adherence"},{"key":"836_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-025-00760-8","author":"C Oedingen","year":"2025","unstructured":"Oedingen C, MacDonald KV, Stein BD, Batist G, Cheung WY, Gill S, et al. Patient preferences for metastatic colorectal cancer treatment: a multi-method approach using discrete choice experiments and best\u2013worst scaling. Patient (Auckl). 2025. https:\/\/doi.org\/10.1007\/s40271-025-00760-8.","journal-title":"Patient (Auckl)"},{"key":"836_CR49","doi-asserted-by":"publisher","first-page":"e228788","DOI":"10.1001\/jamanetworkopen.2022.8788","volume":"5","author":"A Leng","year":"2022","unstructured":"Leng A, Maitland E, Wang S, Nicholas S, Lan K, Wang J. Preferences for end-of-life care among patients with terminal cancer in China. JAMA Netw Open. 2022;5:e228788. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8788.","journal-title":"JAMA Netw Open"},{"key":"836_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12955-020-01414-z","volume":"18","author":"Z Mao","year":"2020","unstructured":"Mao Z, Ahmed S, Graham C, Kind P. Exploring subjective constructions of health in China: a Q-methodological investigation. Health Qual Life Outcomes. 2020;18:165. https:\/\/doi.org\/10.1186\/s12955-020-01414-z.","journal-title":"Health Qual Life Outcomes"},{"key":"836_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clml.2024.07.018","volume":"25","author":"A Major","year":"2025","unstructured":"Major A, Dueck AC, Thanarajasingam G. SOHO state of the art updates and next questions | Measuring patient-reported outcomes (PROs) and treatment tolerability in patients with hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2025;25:142\u201355. https:\/\/doi.org\/10.1016\/j.clml.2024.07.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"836_CR52","doi-asserted-by":"publisher","first-page":"107615","DOI":"10.1016\/j.leukres.2024.107615","volume":"147","author":"J Shen","year":"2024","unstructured":"Shen J, Li J, Yang R, Wu S, Mu Z, Ding S, et al. Advances in the treatment of mantle cell lymphoma with BTK inhibitors. Leuk Res. 2024;147:107615. https:\/\/doi.org\/10.1016\/j.leukres.2024.107615.","journal-title":"Leuk Res"},{"key":"836_CR53","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1097\/hs9.0000000000000771","volume":"6","author":"L Laurenti","year":"2022","unstructured":"Laurenti L, Gaidano G, Mauro FR, Molica S, Pasqualetti P, Scarf\u00f2 L, et al. What are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? a patient-physician cross-matching analysis of a discrete choice experiment. Hemasphere. 2022;6:e771. https:\/\/doi.org\/10.1097\/hs9.0000000000000771.","journal-title":"Hemasphere"},{"key":"836_CR54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/rmhp.S456585","volume":"17","author":"J Mi","year":"2024","unstructured":"Mi J, Du X, Aili Y, Li M, Liu Y. Unveiling patient trust in physicians across China: insights from a nationwide cross-sectional study. Risk Manag Healthc Policy. 2024;17:1039\u201352. https:\/\/doi.org\/10.2147\/rmhp.S456585.","journal-title":"Risk Manag Healthc Policy."},{"key":"836_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/00469580211059984","author":"R Xu","year":"2021","unstructured":"Xu R, Mu T, Jian W, Xu C, Shi J. Knowledge, attitude, and prescription practice on antimicrobials use among physicians: a cross-sectional study in eastern China. Inquiry. 2021. https:\/\/doi.org\/10.1177\/00469580211059984.","journal-title":"Inquiry"},{"key":"836_CR56","doi-asserted-by":"publisher","first-page":"111998","DOI":"10.1016\/j.mad.2024.111998","volume":"222","author":"F Mancinetti","year":"2024","unstructured":"Mancinetti F, Marinelli A, Boccardi V, Mecocci P. Challenges of infectious diseases in older adults: from immunosenescence and inflammaging through antibiotic resistance to management strategies. Mech Ageing Dev. 2024;222:111998. https:\/\/doi.org\/10.1016\/j.mad.2024.111998.","journal-title":"Mech Ageing Dev"},{"key":"836_CR57","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","volume":"11","author":"HR Abrams","year":"2021","unstructured":"Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, et al. Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med. 2021;11:2043\u201354. https:\/\/doi.org\/10.1093\/tbm\/ibab091.","journal-title":"Transl Behav Med"},{"key":"836_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jama.288.6.756","volume":"288","author":"DL Roter","year":"2002","unstructured":"Roter DL, Hall JA, Aoki Y. Physician gender effects in medical communication: a meta-analytic review. JAMA. 2002;288:756\u201364. https:\/\/doi.org\/10.1001\/jama.288.6.756.","journal-title":"JAMA"},{"key":"836_CR59","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00001888-200308000-00003","volume":"78","author":"P Croskerry","year":"2003","unstructured":"Croskerry P. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med. 2003;78:775\u201380. https:\/\/doi.org\/10.1097\/00001888-200308000-00003.","journal-title":"Acad Med"},{"key":"836_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1037\/a0016755","volume":"64","author":"D Kahneman","year":"2009","unstructured":"Kahneman D, Klein G. Conditions for intuitive expertise: a failure to disagree. Am Psychologist. 2009;64:515\u201326. https:\/\/doi.org\/10.1037\/a0016755.","journal-title":"Am Psychologist"},{"key":"836_CR61","doi-asserted-by":"publisher","first-page":"e2229521","DOI":"10.1001\/jamanetworkopen.2022.29521","volume":"5","author":"AS Begin","year":"2022","unstructured":"Begin AS, Hidrue MK, Lehrhoff S, Lennes IT, Armstrong K, Weilburg JB, et al. Association of self-reported primary care physician tolerance for uncertainty with variations in resource use and patient experience. JAMA Netw Open. 2022;5:e2229521. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.29521.","journal-title":"JAMA Netw Open"},{"key":"836_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2018-008390","author":"R Lawton","year":"2019","unstructured":"Lawton R, Robinson O, Harrison R, Mason S, Conner M, Wilson B. Are more experienced clinicians better able to tolerate uncertainty and manage risks? A vignette study of doctors in three NHS emergency departments in England. BMJ Qual Saf. 2019. https:\/\/doi.org\/10.1136\/bmjqs-2018-008390.","journal-title":"BMJ Qual Saf"},{"key":"836_CR63","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jval.2022.01.012","volume":"25","author":"C Vass","year":"2022","unstructured":"Vass C, Boeri M, Karim S, Marshall D, Craig B, Ho KA, et al. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report. Value Health. 2022;25:685\u201394. https:\/\/doi.org\/10.1016\/j.jval.2022.01.012.","journal-title":"Value Health."},{"key":"836_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40273-012-0015-4","volume":"31","author":"JP Grutters","year":"2013","unstructured":"Grutters JP, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31:111\u201323. https:\/\/doi.org\/10.1007\/s40273-012-0015-4.","journal-title":"Pharmacoeconomics"},{"key":"836_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2024.100489","volume":"51","author":"S Boxebeld","year":"2024","unstructured":"Boxebeld S. Ordering effects in discrete choice experiments: a systematic literature review across domains. J Choice Model. 2024;51:100489. https:\/\/doi.org\/10.1016\/j.jocm.2024.100489.","journal-title":"J Choice Model"},{"key":"836_CR66","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40271-023-00625-y","volume":"16","author":"J Veldwijk","year":"2023","unstructured":"Veldwijk J, Marceta SM, Swait JD, Lipman SA, de Bekker-Grob EW. Taking the shortcut: simplifying heuristics in discrete choice experiments. The Patient Patient-Centered Outcomes Res. 2023;16:301\u201315. https:\/\/doi.org\/10.1007\/s40271-023-00625-y.","journal-title":"The Patient Patient-Centered Outcomes Res"},{"key":"836_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10640-004-3332-z","volume":"30","author":"JJ Murphy","year":"2005","unstructured":"Murphy JJ, Allen PG, Stevens TH, Weatherhead D. A meta-analysis of hypothetical bias in stated preference valuation. Environ Resour Econ. 2005;30:313\u201325. https:\/\/doi.org\/10.1007\/s10640-004-3332-z.","journal-title":"Environ Resour Econ"},{"key":"836_CR68","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104:e68-71. https:\/\/doi.org\/10.3324\/haematol.2018.198812.","journal-title":"Haematologica"},{"key":"836_CR69","doi-asserted-by":"publisher","first-page":"7514","DOI":"10.1200\/JCO.2023.41.16_suppl.7514","volume":"41","author":"NN Shah","year":"2023","unstructured":"Shah NN, Jurczak W, Zinzani PL, Eyre TA, Cheah C, Ujjani CS, et al. Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1\/2 BRUIN study with >3 years follow-up from start of enrollment. J Clin Oncol. 2023;41:7514\u20137514. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7514.","journal-title":"J Clin Oncol"},{"key":"836_CR70","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42:1146\u201357. https:\/\/doi.org\/10.1200\/JCO.23.02214.","journal-title":"J Clin Oncol"},{"key":"836_CR71","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555\u201367. https:\/\/doi.org\/10.1200\/JCO.21.02370.","journal-title":"J Clin Oncol"},{"key":"836_CR72","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R\u2010BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189:684\u20138. https:\/\/doi.org\/10.1111\/bjh.16416.","journal-title":"Br J Haematol"},{"key":"836_CR73","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988\u201397. https:\/\/doi.org\/10.1200\/JCO.23.00562.","journal-title":"J Clin Oncol"},{"key":"836_CR74","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2023-178430","volume":"142","author":"Y Song","year":"2023","unstructured":"Song Y, Zhou K, Li L, Liang A, Qin Y, Xia Z, et al. Safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with relapsed\/refractory mantle cell lymphoma (r\/r MCL): updated results from a phase II open-label study in China. Blood. 2023;142:3024. https:\/\/doi.org\/10.1182\/blood-2023-178430.","journal-title":"Blood"},{"key":"836_CR75","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"key":"836_CR76","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2023-174956","volume":"142","author":"ML Wang","year":"2023","unstructured":"Wang ML, Assouline S, Kamdar M, Ghosh N, Naik S, Nakhoda SK, et al. Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study. Blood. 2023;142:734. https:\/\/doi.org\/10.1182\/blood-2023-174956.","journal-title":"Blood"},{"key":"836_CR77","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","volume":"42","author":"TJ Phillips","year":"2024","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trneny M, et al. Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): updated analysis from a phase I\/II study. JCO. 2024;42:7008\u20137008. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7008.","journal-title":"JCO"},{"key":"836_CR78","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"key":"836_CR79","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas. Actas Dermosifiliogr. [cited 2026 Mar 16]. http:\/\/www.actasdermo.org\/es-using-common-terminology-criteria-for-articulo-S1578219020303784. Accessed 16 Mar 2026."},{"key":"836_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-136158","volume":"136","author":"ML Palomba","year":"2020","unstructured":"Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend NHL 001. Blood. 2020;136:10\u20131. https:\/\/doi.org\/10.1182\/blood-2020-136158.","journal-title":"Blood"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00836-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:01:00Z","timestamp":1786708860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00836-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":80,"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00836-z","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered as potential competing interests: Shunping Li reports financial support was provided by Eli Lilly and Company. Li Zhou, Lei Liu, Xue Zhang and Xiao Ma are employees of Eli Lilly and Company. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jiachen Shao: Conceptualization, Methodology, Software, Data curation, Formal analysis and Writing\u2014original draft. Hui Peng: Conceptualization, Methodology, Data curation, Validation, Visualization and Writing\u2014review & editing. Li Zhou: Conceptualization, Project administration, Supervision, and Writing\u2014review & editing. Lei Liu & Xiao Ma: Conceptualization and Writing\u2014review & editing. Xue Zhang: Project administration and Writing\u2014review & editing. Zhiming Li & Shunping Li: Conceptualization, Funding acquisition, Resources and Supervision.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval granted by the Center for Health Management and Policy Research, Shandong University (ECSHCMSDU20240903).","order":3,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data is available per reasonable request.","order":4,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}}]}}